Skip to content
MarketNewsAPI
Product Live news Screener Coverage Pricing
Docs Overview REST API WebSocket API MCP server
Resources Use cases Blog Changelog Status Compare Contact
Log in Get API key Dashboard
MNAT$37.50+0.10(+0.27%)Marquette National Corporation Reports Third Quarter 2026 Results[5:04:00 AM ET]MGA$64.70+0.71(+1.11%)Magna Announces Strong Third Quarter Results[5:00:00 AM ET]EVAX$3.03-0.08(-2.57%)Evaxion receives International Prix Galien Award for AI-Immunology™ as best digital health solution[4:00:00 AM ET]SSL$17.25+0.24(+1.41%)Sasol International Chemicals Achieves Beneficial Operation of ISOSIV Paraffin Unit in Italy[4:00:00 AM ET]TTE$95.31+1.28(+1.36%)Nigeria: TotalEnergies Strengthens Its Partnership with SAPETRO to Support the Fast Development of OPL257[3:56:00 AM ET]NNDNF$14.000.00(0.00%)Nidec Announces the Status of the Development and Operation of the Internal Management System[3:55:00 AM ET]GMTLF$1.10+0.03(+2.80%)Guardian Metal Resources PLC Announces Option Exercise[3:30:00 AM ET]

EVAX · NASDAQ

Evaxion Biotech A/S

$3.03 -0.06 (-1.94%)

Company overview

Evaxion Biotech A/S is a clinical-stage biotech company that develops artificial intelligence-powered immunotherapies for cancers, bacterial diseases, and viral infections. The company develops EVX-01, a cancer immunotherapy in clinical Phase IIb trial for metastatic melanoma; EVX-02, a DNA-based cancer immunotherapy in Phase IIa trial for adjuvant melanoma; and EVX-03, a DNA-based immunotherapy for various cancers. Its pipeline also includes EVX-B1, EVX-B2, and EVX-V1, which are vaccines in pre-clinical development for bacterial and viral diseases. The company was incorporated in 2008 and is headquartered in Hørsholm, Denmark.

Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Market cap
$19.1M
Employees
46
Headquarters
Horsholm
Website
evaxion-biotech.com
CEO
Helen Katrina Tayton-Martin
Listed
February 5, 2021
P/E
-1.98
Dividend yield
0.00%

Company financials

Revenue
$7.5M
Gross profit
$7.5M
Operating income
-$9.2M
EBITDA
-$10.9M
Net income
-$9.8M
EPS
-$1.53
Total assets
$28.4M
Total debt
$7.5M
Gross margin
100.00%
Net margin
-129.63%
Earnings yield
-50.50%

Price chart

2.643.193.744.284.83
EVAX 1D NASDAQ O3.11H3.16L3.03C3.09-0.02 (-0.64%)Vol7.65K

News

15-min delaySigned-out view is delayed 15 minutes. Log in on Pro for the live news desk.

Start 7-day free trial See live plans
Source
Date
Type
Ticker Type Headline Source Published
EVAXEvaxion Biotech A/S Press release Evaxion receives International Prix Galien Award for AI-Immunology™ as best digital health solution GlobeNewswire
EVAXEvaxion Biotech A/S Stock news Evaxion A/S (EVAX) Discusses EVX-01 Phase II Clinical and Immune Data in Advanced Melanoma Transcript Seeking Alpha
EVAXEvaxion Biotech A/S Stock news Evaxion A/S (NASDAQ:EVAX) Shares Break Below 200 Day Moving Average – What’s Next? Defense World
EVAXEvaxion Biotech A/S Press release Evaxion announces 89% vaccine target precision and sustained T-cell and clinical responses at three-year follow-up in phase 2 trial with personalized cancer vaccine EVX-01 GlobeNewswire
EVAXEvaxion Biotech A/S Press release Evaxion reports sustained clinical responses for all patients at three-year follow-up in phase 2 trial with personalized cancer vaccine EVX-01 GlobeNewswire
EVAXEvaxion Biotech A/S Press release Evaxion will present new immune data for personalized GlobeNewswire
EVAXEvaxion Biotech A/S Stock news Analyzing Nektar Therapeutics (NASDAQ:NKTR) & Evaxion A/S (NASDAQ:EVAX) Defense World
EVAXEvaxion Biotech A/S Press release Evaxion applies its AI-Immunology™ platform in autoimmune diseases GlobeNewsWire
EVAXEvaxion Biotech A/S Stock news Evaxion A/S (EVAX) Q2 2026 Earnings Call Transcript Seeking Alpha
EVAXEvaxion Biotech A/S Press release Evaxion announces business update and second quarter 2026 financial results GlobeNewsWire
EVAXEvaxion Biotech A/S Press release Evaxion expands and refocuses R&D pipeline with EVX-05, an AI-designed off-the-shelf brain cancer vaccine program GlobeNewsWire
EVAXEvaxion Biotech A/S Press release Evaxion to announce business update and second quarter 2026 financial results on August 20, 2026 GlobeNewsWire
EVAXEvaxion Biotech A/S Press release Evaxion to present three-year clinical efficacy data for personalized cancer vaccine EVX-01 at the ESMO Congress 2026 GlobeNewsWire
EVAXEvaxion Biotech A/S Press release Evaxion presents new preclinical data for cytomegalovirus vaccine program EVX-V1 GlobeNewsWire
EVAXEvaxion Biotech A/S Press release Evaxion to present new preclinical data for cytomegalovirus vaccine candidate EVX-V1 at the International Herpesvirus Workshop GlobeNewsWire
EVAXEvaxion Biotech A/S Press release Evaxion to present new data for EVX-04, an off-the-shelf therapeutic vaccine for acute myeloid leukemia, at the EHA 2026 Congress GlobeNewsWire
EVAXEvaxion Biotech A/S Stock news Evaxion A/S (EVAX) Q1 2026 Earnings Call Transcript Seeking Alpha
EVAXEvaxion Biotech A/S Press release Evaxion announces business update and first quarter 2026 financial results GlobeNewsWire
EVAXEvaxion Biotech A/S Press release Evaxion to announce business update and first quarter 2026 financial results on May 7, 2026 GlobeNewsWire
EVAXEvaxion Biotech A/S Press release Evaxion promotes Birgitte Rønø to joint role of Chief Scientific and Chief Operating Officer GlobeNewsWire
See more
FAQ

Questions about Evaxion Biotech A/S

What does Evaxion Biotech A/S do?
Evaxion Biotech A/S is a clinical-stage biotech company that develops artificial intelligence-powered immunotherapies for cancers, bacterial diseases, and viral infections. The company develops EVX-01, a cancer immunotherapy in clinical Phase IIb trial for metastatic melanoma; EVX-02, a DNA-based cancer immunotherapy in Phase IIa trial for adjuvant melanoma; and EVX-03, a DNA-based immunotherapy for various cancers. Its pipeline also includes EVX-B1, EVX-B2, and EVX-V1, which are vaccines in pre-clinical development for bacterial and viral diseases. The company was incorporated in 2008 and is headquartered in Hørsholm, Denmark.
What is EVAX's market cap?
Evaxion Biotech A/S (EVAX) is a listed stock with a live quote. The latest market cap on this page is $19.1M.
Where is Evaxion Biotech A/S headquartered?
Evaxion Biotech A/S is headquartered in Horsholm.
How do I get EVAX news from the API?
Call GET /v1/news?tickers=EVAX. Add type=news, type=press_release, or type=legal to take one feed. Pro keys search articles since 2020 in real time. Free keys are delayed 15 minutes and return the last year. Signed-out visitors and Free accounts see that same year on this page. Pro sees articles since 2020.
How far back does EVAX news go?
Signed-out visitors and Free accounts see the last year of stock news, press releases, and legal notices for EVAX, 15 minutes behind, and each headline links to the publisher. Pro, including the 7-day trial, sees articles since 2020 as headlines are ingested. A Free API key returns the last year. Pro keys search articles since 2020.
Is the EVAX price on this page from the API?
The price and daily change update during the US session for every visitor. That quote is context on this page. It is not part of the news API. The chart is one candle per session from the start of 2020. 1W, 1M, and 1Y group those sessions.
Can I use the Pro plan commercially?
No. The Pro plan cannot be used for commercial work. A product you sell, work you do for a client, or redistribution of the feed needs a custom plan and a license. Email [email protected].

Real-time stock news for $15 a month.

Start a 7-day Pro trial. A card is required. REST, WebSocket, and MCP are included, with 1,000 REST requests a day. You won't be charged during the trial. Unless you cancel, the card is billed for Pro when it ends.

Start 7-day free trial Read the docs